Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04880863 is registered in ClinicalTrials.gov with NeoTX Therapeutics Ltd. as lead sponsor.

NCT NCT04880863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04880863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
NeoTX Therapeutics Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2021
Completion date
January 30, 2024
Enrollment
38 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer